ALL SCT FORUM Registry 2022

Allogene Stammzelltransplantationen bei Kindern und Jugendlichen sollten weiterhin zentral im Rahmen der FORUM-Registerstudie dokumentiert werden, bis eine Nachfolgestudie eröffnet wird.

• Patients with ALL (except patients with mature B-ALL) who fulfil the following criteria: Indication for allogeneic SCT according to the frontline treatment consortium and
• Age at diagnosis up to 18 years or age at HSCT up to 21 years
• Indication for allogeneic HSCT according to the national frontline protocols (Germany: AIEOP-BFM ALL 2009, IntReALL SR 2010, Interfant 2006, CoALL and ALL REZ BFM 2002)
• Complete remission (CR) before SCT
• Written consent by the parents (legal guardian) and, if necessary, by the minor patient via “Informed Consent Form”
• No pregnancy
• No secondary malignancy
• No previous HSCT
• HSCT is performed in a centre participating in the registry
• Patients with severe concomitant disease (e.g. malformation syndromes, cardiac malformations, metabolic disorders) can be included, but the intensity of conditioning regimen should be considered on an individual patient basis on the discretion of the treating physician; this can be discussed with the coordinating investigator for the respective patient.
• Patients with Karnofsky / Lansky score under 50 % can be included, but the intensity of conditioning regimen should be considered on an individual patient basis on the discretion of the treating physician; this can be discussed with the coordinating investigator for the respective patient.

• Patients who do not fulfil the inclusion criteria
• Non Hodgkin-Lymphoma
• Severe renal impairment (GFR under 30 % predicted for age)
• Severe liver insufficiency
• Pregnancy
• The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
• No consent is given for saving and propagation of anonymous medical data for study reasons
• Subjects unwilling or unable to comply with the study procedures